Roche dismisses Novo Nordisk as potential threat on lucrative hemophilia market

Novo Nordisk's future hemophilia drugs face a difficult challenge in reconquering the profitable hemophilia drug market, says CEO at Roche, which is currently shepherding a big part of the loyal hemophiliac flock.

Photo: Roche / PR

The pharmaceutical giant Roche has in a short time seized large portions of the world's hemophiliac market, a lead that the Swiss company and competitor of Novo Nordisk expects to maintain.

Even if a company like Novo Nordisk should succeed in sending to market another hemophilia drug, which looks better on paper than Roche's Hemlibra, says CEO Bill Anderson at Roche Pharmaceuticals.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs